德谷胰岛素与甘精胰岛素对2型糖尿病患者TIR影响的对比研究  

A Comparative Study of the Effects of Insulin Degludec and Insulin Glargine on TIR in Patients with Type 2 Diabetes

作　　者：王素妍 刘海霞[1] 蔡填[1] 温影珍 WANG Suyan;LIU Haixia;CAI Tian;WEN Yingzhen(Department of Endocrinology,Huizhou Third People's Hospital,Huizhou,Guangdong Province,516002 China)

机构地区：[1]惠州市第三人民医院内分泌科,广东惠州516002

出　　处：《糖尿病新世界》2021年第22期1-4,共4页Diabetes New World Magazine

基　　金：广东省惠州市科技计划项目(2020Y218)。

摘　　要：目的探讨德谷胰岛与甘精胰岛素对2型糖尿病患者血糖在目标范围的时间(TIR)的影响。方法随机纳入该院2020年1月—2021年9月收治的48例2型糖尿病患者,随机分为两组,每组24例,两组均进行基础胰岛素+降糖药的血糖控制治疗,德谷组使用德谷胰岛素,甘精组使用甘精胰岛素,连续治疗12周后监测两组患者的TIR、治疗前后的糖化血红蛋白(HbA1c),空腹血糖(FPG),餐后2 h血糖(2 h PG),低血糖发生次数、发生率等指标。结果德谷组患者TIR高于甘精组,德谷组低血糖(包括严重低血糖、夜间低血糖等)发生率低于甘精组,差异有统计学意义(P<0.05),但治疗前后两组的FPG,2 h PG以及HbA1c对比,差异无统计学意义(P>0.05)。结论德谷胰岛素能够使2糖尿病患者TIR维持在更佳的水平,并且德谷胰岛素的安全性更高,德谷胰岛素对2型糖尿病患者而言比甘精胰岛素具有更好的临床应用价值。Objective To investigate the effect of Insulin Degludec and insulin glargine on the time when blood sugar with the target ramge(TIR) in patients with type 2 diabetes. Methods A total of 48 patients with type 2 diabetes who were admitted to the hospital from January 2020 to September 2021 were randomly enrolled. They were randomly divided into two groups,with 24 patients in each group. Both groups were treated with basal insulin + hypoglycemic drugs for blood glucose control,the Degludec group was treated with Insulin Degludec, and the glargine group was treated with insulin glargine. After 12 weeks of continuous treatment, the TIR, glycosylated hemoglobin(HbA1 c), fasting blood sugar(FPG) before and after treatment, blood glucose at 2 h after meal(2 h PG), the number of occurrences of hypoglycemia, and the incidence rate of the two groups of patients were monitored. Results The TIR of the Degludec group was higher than that of the Glargine group, and the incidence of hypoglycemia(including severe hypoglycemi a, nocturnal hypoglycemia, etc.) in the Degludec group was lower than that of the Glargine group, the difference was statistically significant(P<0.05). But the FPG,2 h PG and HbA1 c were before and after treatment compared between the two groups, the difference was not statistically significant(P>0.05). Conclusion Insulin degludec can maintain a better level of TIR in patients with type 2 diabetes, and the safety of insulin degludec is higher. Insulin degludec has better clinical application value than insulin glargine for patients with type 2 diabetes.

关 键 词：德谷胰岛素 甘精胰岛素 2型糖尿病 TIR 

分 类 号：R587.1[医药卫生—内分泌]